Edition:
United Kingdom

Sawai Pharmaceutical Co Ltd (4555.T)

4555.T on Tokyo Stock Exchange

6,180JPY
17 Nov 2017
Change (% chg)

¥50 (+0.82%)
Prev Close
¥6,130
Open
¥6,120
Day's High
¥6,200
Day's Low
¥6,070
Volume
278,100
Avg. Vol
186,080
52-wk High
¥6,700
52-wk Low
¥5,700

Select another date:

Mon, Nov 13 2017

REFILE-TABLE-Sawai Pharmaceutical- 6-MTH group results

(Adds company forecast. Accounting policy for forecast is IFRS) Nov 13 (Reuters)- Sawai Pharmaceutical Co Ltd CONSOLIDATED FINANCIAL HIGHLIGHTS (in billions of yen unless specified) 6 months ended 6 months ended Year to Sep 30, 2017 Sep 30, 2016 Mar 31, 2018 LATEST YEAR-AGO LATEST RESULTS RESULTS FORECAST Sales 70.76 65.42

BRIEF-Sawai Pharmaceutical to sell 20 pct stake in SAWAI AMERICA for $211 mln

* Says it plans to sell 20 percent stake in a wholly owned U.S.-based unit SAWAI AMERICA INC to Sumitomo Corporation of Americas, a wholly owned unit of SUMITOMO CORPORATION, for $211 million (23.2 billion yen)

BRIEF-Upsher-Smith says parent co to manufacture migraine medication in Japan With AstraZeneca

* Upsher-Smith Laboratories says co's parent Sawai Pharmaceutical entered agreement with AstraZeneca to manufacture & market migraine medication in Japan​

REFILE-TABLE-Sawai Pharmaceutical-Q1 group results

(Adds company forecast. Accounting policy for forecast is IFRS) Aug 14 (Reuters)- Sawai Pharmaceutical Co Ltd CONSOLIDATED FINANCIAL HIGHLIGHTS (in billions of yen unless specified) 3 months ended 3 months ended Year to Jun 30, 2017 Jun 30, 2016 Mar 31, 2018 LATEST YEAR-AGO LATEST RESULTS RESULTS FORECAST Sales 33.65 32.95 

BRIEF- Sawai Pharmaceutical completes acquisition of Upsher-Smith Laboratories for $1.05 bln

* Says it acquired U.S.-based company Upsher-Smith Laboratories, LLC, which is engaged in manufacture and sales of generic drug, for $1.05 billion (about 116.5 billion yen), on May 31 (U.S. local time)

Select another date: